Anti Inflammatory News and Research

RSS

Entomologist to study how immune system responds to rickettsial infection

Summer for most people means time spent outdoors, which could also mean increased exposure to bugs and, possibly, arthropod-borne diseases, such as "rickettsial diseases" - infectious diseases spread by bacteria, which, generally, are transmitted by lice, fleas, ticks and mites.

5 Aug 2011

Virginia Tech student receives prestigious award for cellular signaling receptor study linked to diabetes, obesity

Stephanie Nicole "Nikki" Lewis, a graduate student in the interdisciplinary doctoral program in genetics, bioinformatics, and computational biology at Virginia Tech, has been awarded the prestigious Ruth L. Kirschstein National Research Service Award for Predoctoral Research through the National Institutes of Health for her study of a cellular signaling receptor that is associated with chronic inflammatory diseases such as diabetes, obesity, and inflammatory bowel disease.

5 Aug 2011

FDA grants Orphan Drug Designation to Kamada's AAT product for type 1 diabetes

Kamada LTD., a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, was granted an Orphan Drug Designation for its Alpha-1 Antitrypsin (AAT) product to treat type 1 diabetes.

5 Aug 2011

NSF awards WSU researcher CAREER grant to develop neural implants

Neural implants have the potential to treat disorders and diseases that typically require long-term treatment, such as blindness, deafness, epilepsy, spinal cord injury, and Alzheimer's and Parkinson's. However, implantable devices have been problematic in clinical applications because of bodily reactions that limit device functioning time.

4 Aug 2011

Biotica acquires full rights to rapamycin analogue program from Pfizer

Biotica Technology Ltd. today announced that it has regained full rights from Pfizer Inc. to its rapamycin analogue program, including transfer of data and materials.

3 Aug 2011

Study links indoor air cleaner use with improved asthma symptoms in children

A Johns Hopkins Children's Center study of Baltimore City children who have asthma and live with smokers shows that indoor air cleaners can greatly reduce household air pollution and lower the rates of daytime asthma symptoms to those achieved with certain anti-inflammatory asthma drugs.

3 Aug 2011

BARDA awards contracts for development of drugs for radiation injury to the GI tract

The first two contracts for advanced development of drugs to treat gastrointestinal (GI) tract injuries associated with acute radiation syndrome were awarded today by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).

2 Aug 2011

Azithromycin may predispose cystic fibrosis patients to mycobacterial infection

Azithromycin is an antibiotic that also has antiinflammatory properties. It is these antiinflammatory properties that are thought to account for the improvement in clinical outcome observed when patients with chronic lung diseases such as cystic fibrosis are treated long-term with azithromycin.

2 Aug 2011

Can-Fite commences CF101 phase 2/3 trial for treatment of Psoriasis

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, ophthalmic, and liver diseases, traded on the Tel Aviv Stock Exchange announced today that it has commenced patient enrolment in a phase 2/3 clinical trial of CF101 for the treatment of Psoriasis.

2 Aug 2011

UH Rainbow physicians to participate in two new clinical trials with AsthmaNet

Physicians at University Hospitals (UH) Rainbow Babies and Children's Hospital are participating in two new clinical trials with the national research consortium AsthmaNet.

30 Jul 2011

Anthera reports increase in second quarter total operating expenses to $22.7 million

Anthera Pharmaceuticals, Inc., today announced financial results and business highlights for the quarter ended June 30, 2011.

29 Jul 2011

POZEN reports revenue of $4.6 million for second quarter 2011

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the second quarter ended June 30, 2011.

28 Jul 2011

Ceridia completes CER006 Phase 1 Proof-of-Concept study in humans

Ceridia Pty Ltd., a biotechnology company focused on reformulating and developing therapeutic drugs, announce the successful completion of Phase 1 Proof-of-Concept study of its novel LipoCeramic ibuprofen formulation, CER006.

27 Jul 2011

Adamis receives U.S. patent for APC-100 to treat prostate cancer

Adamis Pharmaceuticals Corporation, today announced the technology which constitutes its compound APC-100 was recently granted a patent in the United States.

22 Jul 2011

Microencapsulated cell transplant can help treat chronic illnesses more effectively

Chronic illnesses such as Alzheimer's or Parkinson's could be treated more effectively in the future, by means of the transplant of microencapsulated cells. The researcher from the University of the Basque Country (UPV/EHU) Dr Ainhoa Murua has presented a number of proposals for optimising this technique.

21 Jul 2011

Convergence initiates CNV1014802 Phase II study in lumbosacral radiculopathy

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announces that the Phase II proof of concept study with CNV1014802 for treating pain associated with lumbosacral radiculopathy (LSR) has started.

19 Jul 2011

Shionogi to acquire Victory Pharma's products to treat pain and infectious diseases

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced that it has entered into an agreement to acquire all currently marketed products from Victory Pharma, Inc., including seven treatments for pain and two for infectious diseases. The products, which are all approved by the Food and Drug Administration (FDA), will be marketed by Shionogi's existing sales force.

18 Jul 2011